Stocks · News reference
Taysha Gene Therapies Announces Commercial Supply Agreement With Catalent For Rett Syndrome Gene Therapy TSHA-102 Ahead Of Potential FDA Approval
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 3, 2026, 12:01 PM
- Checked
- Aug 3, 2026, 12:01 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Taysha Gene Therapies Q2 EPS $(0.13) Misses $(0.12) Estimate
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 44.44 percent decrease over losses of $(0.09) per
Read original at benzingaGoldman Sachs Maintains Buy on Taysha Gene Therapies, Raises Price Target to $13
Goldman Sachs analyst Salveen Richter maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $11 to $13.
Read original at benzinga